Friday, October 8, 2010 (Last Updated: 10/11/2010)
FRIDAY, Oct. 8 (HealthDay News) -- Androgen deprivation therapy (ADT) for prostate cancer is associated with bone deterioration, and a new technology may help identify men at risk for fractures related to this deterioration, according to a study published online Sept. 29 in the Journal of Clinical Endocrinology & Metabolism.
Emma J. Hamilton, of the University of Melbourne in Australia, and colleagues used high resolution peripheral quantitative computed tomography (HR-pQCT), a new imaging technique, to study changes in the microarchitecture of bones in 26 men with non-metastatic prostate cancer receiving ADT. The researchers calculated volumetric bone mineral density at the distal radius and distal tibia.
By the end of the year of treatment, the researchers found that total volumetric density had decreased by a mean 5.2 percent at the distal radius and by 4.2 percent at the distal tibia. This loss of total density resulted from decreases in cortical volumetric bone mineral density by 11.3 percent at the radius and 6.0 percent at the tibia, and decreases in trabecular density by 3.5 percent at the radius and 1.5 percent at the tibia. Total testosterone was independently related to total and corrected cortical volumetric bone mineral density at the tibia, but estradiol levels were not. The authors note that HR-pQCT may be useful for identifying men at risk for fractures.
"Men on ADT for prostate cancer are at increased risk of fractures, and assessment of bone microarchitecture by HR-pQCT is likely to be a useful tool to assist fracture prediction in this group. Research is needed regarding the timely identification of those individuals at greatest fracture risk as well as optimal therapeutic strategies," the authors write.
Hematology & Oncology
Copyright © 2010 HealthDay. All rights reserved.